Crinetics Pharmaceuticals, Inc. Peer Comparison

Metric Value Ranking
Market Cap $2.9 Billion 2/16 CYTK
$3.8B		 CRNX
$2.9B		 MRUS
$2.8B		 VRDN
$1.0B		 HARP
$865.1M		 ICVX
$769.0M		 RGNX
$376.9M		 INBX
$160.7M		 LYEL
$124.0M		 ALEC
$102.0M		 BDTX
$87.8M		 TCRR
$58.1M		 KRON
$43.9M		 LIAN
$34.6M		 KZR
$29.8M		 PASG
$21.1M
Gross Margin 0% 9/16 MRUS
100%		 ALEC
100%		 HARP
100%		 KRON
100%		 INBX
100%		 VRDN
100%		 LYEL
100%		 RGNX
70%		 CRNX
0%		 KZR
0%		 TCRR
0%		 BDTX
0%		 PASG
0%		 ICVX
0%		 LIAN
0%		 CYTK
-100%
Profit Margin 0% 1/16 CRNX
0%		 KZR
0%		 TCRR
0%		 BDTX
0%		 PASG
0%		 ICVX
0%		 LIAN
0%		 ALEC
-4%		 HARP
-41%		 CYTK
-100%		 RGNX
-100%		 MRUS
-100%		 KRON
-100%		 INBX
-100%		 VRDN
-100%		 LYEL
-100%
EBITDA margin -100% 2/16 ALEC
-10%		 CRNX
-100%		 KZR
-100%		 TCRR
-100%		 BDTX
-100%		 PASG
-100%		 ICVX
-100%		 LIAN
-100%		 RGNX
-178%		 HARP
-273%		 KRON
-469%		 CYTK
-739%		 MRUS
-963%		 INBX
-47176%		 VRDN
-109367%		 LYEL
-524000%
Quarterly Revenue $0 10/16 ALEC
$54.2M		 RGNX
$21.2M		 CYTK
$16.9M		 MRUS
$9.1M		 HARP
$4.4M		 KRON
$2.3M		 INBX
$100,000		 VRDN
$72,000		 LYEL
$11,000		 CRNX
$0		 KZR
$0		 TCRR
$0		 BDTX
$0		 PASG
$0		 ICVX
$0		 LIAN
$0
Quarterly Earnings -$80.6 Million 14/16 HARP
-$1.8M 		ALEC
-$2.1M 		PASG
-$12.7M 		BDTX
-$16.0M 		KZR
-$20.2M 		ICVX
-$22.0M 		LIAN
-$24.0M 		KRON
-$25.8M 		MRUS
-$30.9M 		TCRR
-$40.4M 		INBX
-$47.9M 		RGNX
-$51.2M 		VRDN
-$79.7M 		CRNX
-$80.6M 		CYTK
-$150.0M 		LYEL
-$191.9M
Quarterly Free Cash Flow -$65.7 Million 13/16 HARP
-$0 		PASG
-$8.5M 		KRON
-$12.8M 		BDTX
-$15.1M 		LIAN
-$16.0M 		KZR
-$16.8M 		ICVX
-$19.0M 		RGNX
-$32.7M 		TCRR
-$40.2M 		INBX
-$43.7M 		LYEL
-$47.3M 		ALEC
-$55.2M 		CRNX
-$65.7M 		MRUS
-$66.7M 		CYTK
-$66.9M 		VRDN
-$73.4M
Trailing 4 Quarters Revenue $1.0 Million 7/16 ALEC
$100.6M		 RGNX
$83.3M		 HARP
$37.3M		 MRUS
$36.1M		 CYTK
$18.5M		 KRON
$9.8M		 CRNX
$1.0M		 VRDN
$302,000		 INBX
$200,000		 LYEL
$61,000		 KZR
$0		 TCRR
$0		 BDTX
$0		 PASG
$0		 ICVX
$0		 LIAN
$0
Trailing 4 Quarters Earnings -$298.4 Million 14/16 ALEC
$54.2M 		RGNX
$21.2M 		CYTK
$16.9M 		MRUS
$9.1M 		HARP
$4.4M 		KRON
$2.3M 		INBX
$100,000 		VRDN
$72,000 		LYEL
$11,000 		CRNX
-$0 		KZR
-$0 		TCRR
-$0 		BDTX
-$0 		PASG
-$0 		ICVX
-$0 		LIAN
-$0
Quarterly Earnings Growth -34% 14/16 ALEC
95% 		HARP
84% 		MRUS
49% 		INBX
49% 		KZR
37% 		PASG
24% 		RGNX
19% 		BDTX
18% 		KRON
-2% 		ICVX
-6% 		CYTK
-10% 		LIAN
-10% 		VRDN
-19% 		CRNX
-34% 		TCRR
-39% 		LYEL
-263%
Annual Earnings Growth -28% 12/16 INBX
778% 		HARP
51% 		LIAN
41% 		PASG
34% 		ALEC
32% 		KRON
28% 		BDTX
21% 		KZR
18% 		RGNX
9% 		ICVX
-4% 		CYTK
-12% 		CRNX
-28% 		VRDN
-29% 		TCRR
-45% 		MRUS
-67% 		LYEL
-67%
Quarterly Revenue Growth 0% 4/16 CYTK
912% 		ALEC
257% 		MRUS
2% 		CRNX
0% 		KZR
0% 		TCRR
0% 		BDTX
0% 		PASG
0% 		VRDN
0% 		ICVX
0% 		LIAN
0% 		KRON
-1% 		RGNX
-4% 		LYEL
-15% 		HARP
-67% 		INBX
-94%
Annual Revenue Growth 0% 5/16 CYTK
558% 		ALEC
137% 		KRON
96% 		VRDN
5% 		CRNX
0% 		TCRR
0% 		BDTX
0% 		PASG
0% 		ICVX
0% 		LIAN
0% 		HARP
-3% 		MRUS
-14% 		RGNX
-24% 		LYEL
-31% 		INBX
-90% 		KZR
-100%
Cash On Hand $264.5 Million 2/16 MRUS
$293.3M 		CRNX
$264.5M 		INBX
$152.6M 		LYEL
$105.6M 		LIAN
$103.5M 		VRDN
$99.6M 		CYTK
$94.9M 		KRON
$84.6M 		ICVX
$63.2M 		RGNX
$57.5M 		KZR
$41.7M 		PASG
$37.6M 		BDTX
$36.4M 		ALEC
$33.0M 		HARP
$17.7M 		TCRR
$14.4M
Short Term Debt $7.2 Million 6/16 CYTK
$30.5M 		ALEC
$8.8M 		KZR
$8.7M 		LYEL
$8.0M 		RGNX
$7.9M 		CRNX
$7.2M 		PASG
$3.7M 		BDTX
$3.4M 		KRON
$3.4M 		TCRR
$3.3M 		HARP
$3.0M 		ICVX
$2.2M 		LIAN
$1.9M 		MRUS
$1.7M 		INBX
$1.6M 		VRDN
$513,000
Long Term Debt $44.6 Million 4/16 CYTK
$758.2M		 RGNX
$74.1M		 LYEL
$51.0M		 CRNX
$44.6M		 ALEC
$33.8M		 PASG
$21.8M		 KRON
$21.5M		 VRDN
$20.6M		 BDTX
$18.8M		 HARP
$11.5M		 MRUS
$8.2M		 KZR
$7.4M		 INBX
$6.5M		 ICVX
$5.9M		 TCRR
$2.7M		 LIAN
$950,000
PE -1.00 2/16 INBX
0.10		 CRNX
-1.00		 CYTK
-1.00		 RGNX
-1.00		 MRUS
-1.00		 ALEC
-1.00		 HARP
-1.00		 KZR
-1.00		 TCRR
-1.00		 BDTX
-1.00		 PASG
-1.00		 KRON
-1.00		 VRDN
-1.00		 LYEL
-1.00		 ICVX
-1.00		 LIAN
-1.00
PS 2764.72 2/16 VRDN
3347.43		 CRNX
2764.72		 LYEL
2033.47		 INBX
803.41		 CYTK
204.93		 MRUS
78.34		 HARP
23.17		 RGNX
4.52		 KRON
4.46		 ALEC
1.01		 KZR
-1.00		 TCRR
-1.00		 BDTX
-1.00		 PASG
-1.00		 ICVX
-1.00		 LIAN
-1.00
PB 2.17 4/16 HARP
190.50		 MRUS
4.37		 ICVX
3.31		 CRNX
2.17		 VRDN
1.51		 RGNX
1.45		 INBX
1.20		 BDTX
1.05		 ALEC
0.80		 TCRR
0.57		 KRON
0.50		 PASG
0.34		 LYEL
0.32		 KZR
0.25		 LIAN
0.15		 CYTK
0.00
PC 10.86 4/16 HARP
48.77		 CYTK
39.91		 ICVX
12.16		 CRNX
10.86		 VRDN
10.15		 MRUS
9.65		 RGNX
6.55		 TCRR
4.02		 ALEC
3.09		 BDTX
2.41		 LYEL
1.17		 INBX
1.05		 KZR
0.71		 PASG
0.56		 KRON
0.52		 LIAN
0.33
Liabilities to Equity 0.08 14/16 HARP
9.48		 ALEC
2.69		 RGNX
0.79		 PASG
0.67		 TCRR
0.50		 BDTX
0.47		 KRON
0.42		 INBX
0.35		 LYEL
0.28		 KZR
0.24		 MRUS
0.21		 LIAN
0.13		 VRDN
0.11		 CRNX
0.08		 ICVX
0.08		 CYTK
0.00
ROA -0.21 2/16 INBX
934% 		CRNX
-21% 		ALEC
-25% 		MRUS
-28% 		LIAN
-33% 		VRDN
-36% 		ICVX
-37% 		CYTK
-42% 		RGNX
-49% 		BDTX
-57% 		KZR
-58% 		PASG
-63% 		HARP
-65% 		KRON
-69% 		LYEL
-70% 		TCRR
-108%
ROE -0.23 3/16 INBX
1263% 		CYTK
435% 		CRNX
-23% 		MRUS
-33% 		VRDN
-40% 		ICVX
-40% 		LIAN
-43% 		KZR
-72% 		BDTX
-84% 		RGNX
-87% 		LYEL
-90% 		ALEC
-94% 		KRON
-98% 		PASG
-106% 		TCRR
-161% 		HARP
-680%
Current Ratio 13.07 2/16 ICVX
13.28		 CRNX
13.07		 VRDN
10.49		 LIAN
9.81		 MRUS
5.81		 KZR
5.21		 LYEL
4.54		 INBX
3.83		 KRON
3.38		 BDTX
3.12		 TCRR
3.02		 PASG
2.49		 RGNX
2.26		 ALEC
1.37		 HARP
1.11		 CYTK
0.91
Quick Ratio 12.33 1/16 INBX
0.10		 CRNX
-1.00		 CYTK
-1.00		 RGNX
-1.00		 MRUS
-1.00		 ALEC
-1.00		 HARP
-1.00		 KZR
-1.00		 TCRR
-1.00		 BDTX
-1.00		 PASG
-1.00		 KRON
-1.00		 VRDN
-1.00		 LYEL
-1.00		 ICVX
-1.00		 LIAN
-1.00
Long Term Debt to Equity 0.03 10/16 HARP}
2.54		 PASG}
0.36		 RGNX}
0.29		 ALEC}
0.27		 KRON}
0.25		 BDTX}
0.23		 LYEL}
0.13		 KZR}
0.06		 INBX}
0.05		 CRNX}
0.03		 TCRR}
0.03		 VRDN}
0.03		 ICVX}
0.03		 MRUS}
0.01		 LIAN}
0.00		 CYTK}
-5.60
Debt to Equity 0.04 11/16 HARP
3.19		 PASG
0.42		 ALEC
0.34		 RGNX
0.32		 KRON
0.28		 BDTX
0.27		 LYEL
0.15		 KZR
0.14		 TCRR
0.06		 INBX
0.06		 CRNX
0.04		 VRDN
0.03		 ICVX
0.03		 MRUS
0.02		 LIAN
0.01		 CYTK
-5.83
Burn Rate 3.14 5/16 MRUS
9.26		 HARP
5.90		 ALEC
5.88		 LIAN
4.21		 CRNX
3.14		 INBX
3.14		 KRON
3.07		 ICVX
2.77		 PASG
2.59		 BDTX
2.07		 KZR
1.84		 VRDN
1.23		 RGNX
1.02		 LYEL
0.54		 CYTK
0.50		 TCRR
0.35
Cash to Cap 0.09 13/16 LIAN
2.99		 KRON
1.93		 PASG
1.78		 KZR
1.40		 INBX
0.95		 LYEL
0.85		 BDTX
0.41		 ALEC
0.32		 TCRR
0.25		 RGNX
0.15		 MRUS
0.10		 VRDN
0.10		 CRNX
0.09		 ICVX
0.08		 CYTK
0.03		 HARP
0.02
CCR 0.82 9/16 ALEC
26.62		 MRUS
2.16		 TCRR
0.99		 BDTX
0.94		 VRDN
0.92		 INBX
0.91		 ICVX
0.86		 KZR
0.83		 CRNX
0.82		 LIAN
0.67		 PASG
0.66		 RGNX
0.64		 KRON
0.50		 CYTK
0.45		 LYEL
0.25		 HARP
0.00
EV to EBITDA -28.31 13/16 KRON}
1.48		 INBX}
-0.34		 KZR}
-1.00		 TCRR}
-1.00		 BDTX}
-1.00		 PASG}
-1.00		 ICVX}
-1.00		 LIAN}
-1.00		 LYEL}
-1.34		 RGNX}
-10.63		 VRDN}
-11.84		 ALEC}
-21.56		 CRNX}
-28.31		 MRUS}
-28.93		 CYTK}
-35.82		 HARP}
-71.00
EV to Revenue 2559.88 2/16 VRDN
3087.50		 CRNX
2559.88		 LYEL
1269.06		 CYTK
242.48		 INBX
80.67		 MRUS
70.50		 HARP
23.08		 RGNX
4.82		 ALEC
1.11		 KZR
-1.00		 TCRR
-1.00		 BDTX
-1.00		 PASG
-1.00		 ICVX
-1.00		 LIAN
-1.00		 KRON
-1.60

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions